Haemonetics Corporation $HAE Shares Bought by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Haemonetics Corporation by 0.9%, acquiring an additional 4,834 shares, bringing its total holdings to 556,027 shares worth approximately $35.3 million.
• Haemonetics Corporation reported $1.10 EPS for the last quarter, surpassing analysts' estimates of $1.01, while revenues decreased by 4.4% year-over-year.
• Several analysts have revised their target prices for Haemonetics, with Mizuho reducing it from $90.00 to $70.00 while Citigroup upgraded their rating to "buy" with a target price of $90.00.

Charles Schwab Investment Management Inc. boosted its position in Haemonetics Corporation (NYSE:HAE - Free Report) by 0.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 556,027 shares of the medical instruments supplier's stock after buying an additional 4,834 shares during the quarter. Charles Schwab Investment Management Inc. owned 1.11% of Haemonetics worth $35,336,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Cary Street Partners Financial LLC acquired a new position in Haemonetics in the 1st quarter worth $1,082,000. XTX Topco Ltd acquired a new position in Haemonetics in the 1st quarter worth $1,947,000. University of Texas Texas AM Investment Management Co. acquired a new position in Haemonetics in the 1st quarter worth $65,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Haemonetics by 7.5% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,396 shares of the medical instruments supplier's stock valued at $851,000 after purchasing an additional 936 shares in the last quarter. Finally, Heartland Advisors Inc. raised its stake in shares of Haemonetics by 67.8% in the 1st quarter. Heartland Advisors Inc. now owns 155,898 shares of the medical instruments supplier's stock valued at $9,907,000 after purchasing an additional 62,975 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Haemonetics Stock Performance

HAE traded up $2.2970 on Friday, hitting $56.2770. 1,147,164 shares of the company's stock were exchanged, compared to its average volume of 1,234,426. The firm has a market cap of $2.71 billion, a PE ratio of 17.21, a P/E/G ratio of 1.04 and a beta of 0.40. Haemonetics Corporation has a twelve month low of $50.68 and a twelve month high of $94.99. The stock has a fifty day moving average of $69.50 and a two-hundred day moving average of $66.29. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.09. The firm had revenue of $321.39 million for the quarter, compared to analyst estimates of $305.12 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. Haemonetics's quarterly revenue was down 4.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.02 earnings per share. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. On average, research analysts anticipate that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HAE has been the topic of a number of recent analyst reports. Baird R W upgraded shares of Haemonetics to a "strong-buy" rating in a research note on Wednesday, June 25th. Citigroup upgraded shares of Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 target price on the stock in a research note on Wednesday, July 9th. Robert W. Baird initiated coverage on shares of Haemonetics in a research note on Thursday, June 26th. They issued an "outperform" rating and a $87.00 target price on the stock. Wall Street Zen lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Finally, Mizuho cut their target price on shares of Haemonetics from $90.00 to $70.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $85.18.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.